184 related articles for article (PubMed ID: 34762523)
41. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
Zhao G; Liu S; Chen S; Ren Z; Li C; Bian J; Wu J; Zhou J; Zhang Y
Drug Deliv; 2021 Dec; 28(1):1356-1362. PubMed ID: 34180755
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis.
Zou JH; Zhang L; Ren ZG; Ye SL
J Dig Dis; 2016 Aug; 17(8):510-517. PubMed ID: 27384075
[TBL] [Abstract][Full Text] [Related]
43. Clinical features and treatment of hepatic abscesses with biloma formation after transcatheter arterial chemoembolization.
Zhu M; Li G; Chen Y; Gong G; Guo W
Arab J Gastroenterol; 2022 Feb; 23(1):32-38. PubMed ID: 35153174
[TBL] [Abstract][Full Text] [Related]
44. Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumors.
Wu GC; Chan ED; Chou YC; Yu CY; Hsieh TY; Hsieh CB; Chian CF; Ke FC; Dai YL; Su WL
Anticancer Drugs; 2014 Sep; 25(8):976-81. PubMed ID: 24736105
[TBL] [Abstract][Full Text] [Related]
45. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
[TBL] [Abstract][Full Text] [Related]
46. Liver Abscess Formation Following Transarterial Chemoembolization: Clinical Features, Risk Factors, Bacteria Spectrum, and Percutaneous Catheter Drainage.
Lv WF; Lu D; He YS; Xiao JK; Zhou CZ; Cheng DL
Medicine (Baltimore); 2016 Apr; 95(17):e3503. PubMed ID: 27124055
[TBL] [Abstract][Full Text] [Related]
47. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres
Peng Z; Cao G; Hou Q; Li L; Ying S; Sun J; Zhou G; Zhou J; Zhang X; Ji W; Yu Z; Li T; Zhu D; Hu W; Ji J; Du H; Shi C; Guo X; Fang J; Han J; Gu W; Xie X; Sun Z; Xu H; Wu X; Hu T; Huang J; Hu H; Zheng J; Luo J; Chen Y; Yu W; Shao G
Oncol Res; 2020 May; 28(3):249-271. PubMed ID: 31856933
[TBL] [Abstract][Full Text] [Related]
48. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
Burrel M; Reig M; Forner A; Barrufet M; de Lope CR; Tremosini S; Ayuso C; Llovet JM; Real MI; Bruix J
J Hepatol; 2012 Jun; 56(6):1330-5. PubMed ID: 22314428
[TBL] [Abstract][Full Text] [Related]
49. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
[TBL] [Abstract][Full Text] [Related]
50. Comparative Study of Drug-eluting Beads versus Conventional Transarterial Chemoembolization for Treating Peculiar Anatomical Sites of Gastric Cancer Liver Metastasis.
Xu H; Min X; Ren Y; Yang L; Liu F
Med Sci Monit; 2020 May; 26():e922988. PubMed ID: 32474569
[TBL] [Abstract][Full Text] [Related]
51. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
[TBL] [Abstract][Full Text] [Related]
52. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
53. Liver abscess following transarterial chemoembolization for the treatment of hepatocellular carcinoma: A retrospective analysis of 23 cases.
Jia Z; Tu J; Cao C; Wang W; Zhou W; Ji J; Li M
J Cancer Res Ther; 2018 Sep; 14(Supplement):S628-S633. PubMed ID: 30249879
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 μm for the Treatment of Hepatocellular Carcinoma.
Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
Anticancer Res; 2018 Feb; 38(2):1025-1032. PubMed ID: 29374736
[TBL] [Abstract][Full Text] [Related]
55. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
56. Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort.
Sandow TA; Arndt SE; Albar AA; DeVun DA; Kirsch DS; Gimenez JM; Bohorquez HE; Gilbert PJ; Thevenot PT; Nunez KG; Galliano GA; Cohen AJ; Kay D; Gulotta PM
Radiology; 2018 Mar; 286(3):1072-1083. PubMed ID: 29206595
[TBL] [Abstract][Full Text] [Related]
57. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.
Pipa-Muñiz M; Sanmartino S; Mesa A; Álvarez-Navascués C; González-Diéguez ML; Cadahía V; Rodríguez JE; Vega F; Rodríguez M; Costilla-García SM; Varela M
BMC Gastroenterol; 2020 Jun; 20(1):166. PubMed ID: 32487071
[TBL] [Abstract][Full Text] [Related]
58. Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study.
Xing M; Kokabi N; Prajapati HJ; Close O; Ludwig JM; Kim HS
J Comp Eff Res; 2016 Mar; 5(2):141-54. PubMed ID: 26946950
[TBL] [Abstract][Full Text] [Related]
59. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
[TBL] [Abstract][Full Text] [Related]
60. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
